Retatrutide: New GLP‑1 combo delivers 28% weight loss in trials

Posted by amber464 in Weight Loss & Metabolic - 1 points, 0 comments.

https://www.cnbc.com/2026/05/21/eli-lilly-weight-loss-drug-retatrutide-clears-obesity-trial.html

The Time article reports that Eli Lilly’s retatrutide, a triple‑hormone weight‑loss drug, just cleared a late‑stage trial. The highest dose achieved a 28.3 % loss in body weight, with a 70‑plus BMI drop for some patients. It’s marketed as a next‑generation GLP‑1 that hits three targets instead of one or two.

I’m excited about the numbers because they dwarf what we see with semaglutide or tirzepatide. Yet the article glosses over that the 28 % was at the top dose, and it doesn’t mention the higher incidence of nausea or the serious, though rare, pancreatitis signals that the FDA flagged. In my own trials with tirzepatide, nausea was the biggest barrier, and I’m wary of a drug that might come with a heavier side‑effect load. The study also omitted real‑world adherence data, only 70 % of participants in the trial stayed on the drug for the full 12 weeks.

What do you think? Would you consider a lower dose if it means a better side‑effect profile, or are the raw percent‑loss numbers too tempting to ignore?

Community discussion - research and educational context only. Not medical advice.